跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2015-002098-40-DE
EUCTR2015-002098-40-DE进行中（未招募）1 期

A Phase 2a, Proof of Concept Trial, testing twice daily application of LEO 124249 ointment 30mg/g in the treatment of mild to moderate inverse psoriasis

EO Pharma A/S0 个研究点开始时间: 2015年12月2日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •1.Provision of signed and dated informed consent prior to any trial specific procedures.
  • •2.Male or female subjects between 18 to 75 years.
  • •3.A diagnosis of stable mild to moderate inverse psoriasis (i.e. axillae, the infra- and intermammary, genital, scrotum, abdominal and retroauricular folds; the intergluteal cleft and perianal skin, in addition to neck or other skin folds). Mild to moderate is defined as having at least score 1 for each individual sign thickness and redness, and total TSS score of at least 5.
  • •4.The total treatment area can be up to 4% BSA (720 cm2).
  • •5.Subjects must have a history of psoriasis, or have psoriasis, or present with characteristic psoriasis leasons elsewhere on the body (including the scalp) at Visit 1 (Screening).
  • •6.Stable inverse psoriasis based on TSS evaluated at Visit 1 (Screening) and at Visit 2 (Start of treatment), which must not differ more than 1 point in any single clinical sign score (redness, scaling and thickness).
  • •7.Except for inverse psoriasis, overall good health including well controlled diseases (e.g. hypertension, diabetes, and thyroid disease) as determined by medical history, physical examination, electrocardiogram (ECG), vital signs (blood pressure, heart rate and body temperature) and clinical laboratory evaluation.
  • •8.Subjects willing and able to follow all the trial procedures and complete the whole trial.
  • •9.Female subjects must be of either:
  • •onon-childbearing potential, i.e. post-menopausal for at least one year, or have a confirmed clinical history of sterility (e.g. the subject is without a uterus or has tubal ligation) or,
  • •ochild-bearing potential (including women less than post menopausal for 1 year) provided there is a confirmed negative pregnancy test prior to trial treatment to rule out pregnancy.
  • •Female subjects of child-bearing potential (and their male partners) and male subjects (and their female partner of childbearing potential) must be willing to use highly effective methods of contraception (pearl index <1%) from Visits 1 (Screening) and until 1 Week after the last administration of IP. Adequate methods of contraception for female and male are defined as follows:
  • •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation for at least one menstrual cycle prior to randomization (Visit 2 (Start of treatment).
  • •ointravaginal
  • •otransdermal
  • •intrauterine device (IUD) for at least one menstrual cycle prior to randomization (Visit 2 Start of treatment).
  • •intrauterine hormone-releasing system (IUS) for at least one menstrual cycle prior to randomization (Visit 2 Start of Treatment).
  • •bilateral tubal occlusion.
  • •vasectomized or vasectomized partner (partner should be sole partner for the subject).
  • •sexual abstinence (when this is in line with the preferred lifestyle of the subject).
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 56
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 10

排除标准

  • •1.Female subjects who are breastfeeding or pregnant.
  • •2.Severe chronic inverse psoriasis, or psoriasis on the body (>30% of BSA).
  • •3.Current diagnosis of acute guttate, erythrodermic, exfoliative or pustular psoriasis.
  • •4.Signs of clinically active infection in any of the inverse psoriasis areas, as judged by the investigator.
  • •5.Disease that has spontaneously and markedly deteriorated or improved between Visit 1 (Screening) and Visit 2 (Start of treatment).
  • •6.Use of biological therapies (marketed/not marketed) with a possible effect on inverse psoriasis within 4 weeks (etanercept), 8 weeks (adalimumab, alefacept, infliximab), 16 weeks (ustekinumab, secukinumab) or 4 weeks/5 half-lives (whichever is longer) for experimental biological products prior to Visit 2 (Start of treatment).
  • •7.Use of systemic treatments (marketed/non-marketed), other than biologics, with a potential effect on inverse psoriasis (e.g., corticosteroids, retinoids, dimethylfumarate, cyclosporine, azathioprine methotrexate, immunosuppressants) within 6 weeks prior to Visit 2 (Start of treatment) (inhaled or intranasal steroids corresponding of up to 1 mg prednisone for asthma or rhinitis may be used).
  • •8.Use of St John’s worth preparations (oral and/or topical) within 2 weeks prior to Visit 2 (Start of treatment).
  • •9.Use of very potent topical corticosteroids (WHO group IV) for the treatment of psoriasis on the body and/or scalp within 4 weeks prior to Visit 2 (Start of treatment).
  • •10.Use of topical medication for the treatment of inverse psoriasis: WHO group I-III corticosteroids, retinoids, vitamin D analogues, immunomodulators (e.g. macrolides, calcineurin), anthracen derivatives, tar, or salicylic acid within 2 weeks prior to Visit 2 (Start of treatment).
  • •11.Exposure to phototherapy (PUVA, UVA, UVB, Grenz Ray therapy) within 4 weeks prior to Visit 2 (Start of treatment).
  • •12.Use of other treatment (drug/non-drug) for inverse psoriasis during the trial, except for the use of IP.
  • •13.Initiation of, or expected changes to concomitant medication, that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) within 2 weeks prior to Visit 2 (Start of treatment).
  • •14.Subjects with a positive HBV score antibody, HBsAg, anti-HCV or anti-HIV test at Visit 1 (Screening) .
  • •15.Subjects with history of an immunocompromising disease (e.g., lymphoma, HIV, Wiskott-Aldrich Syndrome).
  • •16.A marked abnormal ECG, i.e. PR interval > 220 ms, QRS interval >110 ms or corrected QT interval (Bazett, QTcB) > 470 ms for females and > 450 ms for males at Visit 1 (Screening).
  • •17.Supine BP that is over 150/95 mmHg or below 90/50 mmHg at Visits 1 (Screening) and 2 (Start of treatment).
  • •18.Supine heart rate that is over 100 beats per minute (bpm) or below 50 bpm at Visits 1 (Screening) and 2 (Start of treatment).
  • •19.Body temperature (ear, tympanic) >37.5 ºC or < 35.5 ºC at Visits 1 (Screening) and 2 (Start of treatment).
  • •20.Known hepatic dysfunction or hepatic dysfunction tested at Visit 1 (Screening) (e.g. alanine aminotransferase [ALT], aspartate aminotransferase [AST], and gamma glutamyl transpeptidase [GGT] > 2 times the upper limit of normal) .
  • •21.History of concurrent diseases that could interfere with study evaluations or pose a safety concern.
  • •22.Any current dermatological disorder (e.g. serborrhic dermatitis, contact dermatitis, cutaneous mycosos) which may confound the evaluation of inverse psoriasis.

研究者

发起方
EO Pharma A/S

相似试验

进行中（未招募）
1 期
A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 weeks in subjects with moderate-to-severely active axial spondyloarthritis including those previously exposed to anti-TNF therapy (NAMASTE study)moderate-to-severe axial spondyloarthritisMedDRA version: 20.0Level: PTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2018-000176-15-GBIzana Bioscience Limited42
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of oral treatment with PBF-677 in patients with mild to moderate ulcerative colitis.
EUCTR2017-003228-54-ESPaloBiofarma S.L.30
进行中（未招募）
1 期
A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin lymphoma (cHL)Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatmentMedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 100000004864
EUCTR2019-003084-21-ITPROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA27
进行中（未招募）
1 期
Essai de phase II de preuve du concept : Evaluation de l’activité anti-cellules souches cancéreuses du bevacizumab administré en combinaison à la chimiothérapie néoadjuvante dans les cancers du seiTumeurs du sein localement avancées ou inflammatoires candidates à un traitement néo-adjuvant par une association séquentielle FEC/docetaxel .MedDRA version: 12.0Level: LLTClassification code 10006187Term: Breast cancer
EUCTR2009-014773-40-FRInstitut Paoli-Calmettes75
进行中（未招募）
1 期
Study with stem cells from allogenic adipose tissue, in patients with HIV infetion.Infection for HIV with controlled viral load and immunological discordant responseMedDRA version: 18.1 Level: LLT Classification code 10001509 Term: AIDS System Organ Class: 100000004862
EUCTR2014-000307-26-ESIniciativa Andaluza en Terapias Avanzadas-Fundación Pública Andaluza Progreso y Salud15